Sign in Subscribe

Topic

consortium

A collection of 5 issues

ICPC publishes GWAS analysis on platelet reactivity and cardiovascular response in patients treated with clopidogrel

The GWAS analysis on platelet reactivity and cardiovascular outcome for clopidogrel, the third paper by the International Clopidogrel Pharmacogenomics Consortium (ICPC), has just been published in journal Clinical Pharmacology & Therapeutics.Clopidogrel is an antiplatelet agent widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke.

European Union awards €15 million to U-PGx consortium

The European Union H2020 programme has awarded a €15 million grant to the Ubiquitous Pharmacogenomics (U-PGx) consortium for an international pharmacogenomics research and implementation project. The aim of the U-PGx consortium is to make actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen. The objective of the

GWAS on SSRI treatment outcome in patients with depression: ISPC cohort and meta-analysis

The treatment response to selective serotonin reuptake inhibitors (SSRIs), a major class of antidepressant drugs, varies considerably between patients. The International SSRI PharmacogenomicsConsortium (ISPC) was established with the primary goal of identifying genetic variations that may contribute to SSRI treatment outcome in patients with depressive disorder. The ISPC includes eight

CYP2D6 genotype and tamoxifen response: meta-analysis of heterogeneous population

Tamoxifen treatment results in substantial inter-individual variability of outcome, possibly due to genetic variability in CYP2D6. The clinical usefulness of CYP2D6 genotyping for prediction of tamoxifen outcome has not been established because of conflicting reports. This controversy is well illustrated by secondary analyses from 3 large adjuvant tamoxifen trials (ATAC,

Novel SNP in CYP2C cluster associated with warfarin dose in African Americans

The International Warfarin Pharmacogenetics Consortium (IWPC), which involves investigators from eight institutions including Stanford University, has identified a SNP that is associated with warfarin dose requirement in the African American population. As described in Lancet, rs12777823, located in the CYP2C cluster, shows an effect in African Americans that is independent